Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

Can Stem Cell Therapy cure a Traumatic Brain Injury?

No. Stem cell therapy cannot cure a traumatic brain injury (TBI), and no clinic can honestly promise a cure. Neurons and connections lost after a severe injury are not fully replaced by any current treatment.

Free Consultation
Brain location on a neutral human figure

What research shows is that some cell therapies may help improve specific functions in some patients. The most rigorous example is the STEMTRA trial, a randomized, sham-controlled study published in Neurology, in which a modified bone-marrow-derived cell product implanted directly into the brain improved motor function more than sham surgery in people with chronic TBI. That result applies to a specific product and route. At Stem Cell Mexico, TBI protocols use only allogeneic mesenchymal stem cells (MSCs) from Wharton's jelly of the umbilical cord, offered as a supportive treatment that works alongside rehabilitation.

This guide explains why "cure" is the wrong expectation, what improvement can realistically look like, what the evidence supports and how to judge whether treatment makes sense for you.

Why a cure is not a realistic expectation

A TBI happens in two phases. The primary injury is the immediate mechanical damage: bruising, bleeding, tearing of nerve fibers and death of brain cells at the moment of impact. The secondary injury develops over the following hours, days and months: inflammation, swelling, changes in blood flow, oxidative stress and progressive damage to white matter. In many people, a low-grade inflammatory state persists for years.

Cells and tissue destroyed in the primary injury do not come back. The adult brain has very limited ability to produce new neurons, and the complex networks that support movement, memory, language and behavior cannot be rebuilt by an infusion. This is why the term "cure" does not apply to TBI, whether the treatment is medication, surgery, rehabilitation or cell therapy.

What can change is how well the remaining brain works. The brain can reorganize itself through a process called neuroplasticity: surviving areas take over functions, new connections form and existing pathways become more efficient with practice. Most of the recovery people experience after TBI comes from this process, supported by rehabilitation.

What MSCs may do in the injured brain

MSCs from Wharton's jelly do not become new neurons in any meaningful number. Research suggests they act through paracrine signaling, releasing proteins, growth factors and extracellular vesicles that may:

  • Modulate inflammation, reducing activity of the brain's immune cells (microglia) that can sustain damage.
  • Support surviving neurons and their connections through trophic factors.
  • Promote blood vessel formation in damaged areas.
  • Support neuroplasticity, which may make rehabilitation more productive.

These effects are documented mostly in laboratory and animal studies. Translating them into consistent benefit in people is the central challenge of the field, and it depends on cell type, dose, route, timing and the characteristics of each injury.

The route matters

When MSCs are given by intravenous (IV) infusion, a large proportion is trapped temporarily in the lungs, a phenomenon known as the pulmonary first-pass effect. Few cells reach the brain directly. Any effect after IV delivery is believed to come from systemic signaling, for example by calming inflammation throughout the body, rather than from cells settling in the injured tissue. This is one reason results from direct brain implantation, such as STEMTRA, cannot be applied automatically to IV treatment.

What the evidence shows

The STEMTRA trial

  • Who: adults with chronic motor deficits at least one year after TBI.
  • What: SB623, a genetically modified bone-marrow-derived cell product, implanted around the injured area through small openings in the skull, compared with sham surgery.
  • Result: greater improvement on a standardized motor scale at 24 weeks in the treated group. A meaningful share of treated patients achieved a clinically relevant gain, compared with a much smaller share of controls.
  • Regulatory status: Japan granted conditional, time-limited approval for this specific product in 2024. No regulator has approved IV umbilical cord MSCs for TBI.

Other clinical studies

Clinical studies have tested several cell types and routes in TBI, including bone marrow cells and umbilical cord cells delivered intravenously or into the spinal fluid. They generally report acceptable safety and some improvements in neurological or functional scores.

Safety

Large meta-analyses of IV MSC trials, including a 2026 analysis focused on umbilical-cord-derived MSCs, found temporary fever to be the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled studies. No treatment is free of risk, and the medical team reviews each case before treatment. Every procedure carries possible adverse effects, and people with TBI may have additional considerations such as seizures, swallowing problems or reduced mobility.

What realistic improvement can look like

When people with TBI report benefit after cell therapy, changes are usually gradual and partial. Examples include:

  • Small gains in strength, balance or coordination.
  • Better energy and endurance during therapy sessions.
  • Improvements in attention, processing speed or speech in some cases.
  • Changes in sleep, headaches or mood.

Other patients notice no meaningful change. Because some of these areas also improve with time and rehabilitation, progress should be measured with objective scales before and after treatment, not only by impressions.

Factors that influence outcomes

  • Severity and location of the injury: diffuse axonal injury, large contusions or brainstem damage limit recovery potential.
  • Time since injury: the biology of acute, subacute and chronic TBI is different, and results from one phase do not apply to another.
  • Age and overall health: cardiovascular health, diabetes, sleep and nutrition affect the brain's capacity to adapt.
  • Rehabilitation: consistent physical, occupational, speech and cognitive therapy is one of the strongest predictors of progress.
  • Complications: seizures, hydrocephalus, spasticity, depression and hormonal problems can limit recovery if not treated.
  • Realistic goals: clear, measurable goals make it possible to judge whether a treatment helped.

How treatment is done at Stem Cell Mexico

  • Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells, bone marrow, adipose tissue or other cell sources are used.
  • Laboratory: cells are produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
  • Route: usually IV infusion; other routes are considered only when the medical team judges them appropriate for the specific case and protocol.
  • Setting: application under medical supervision with monitoring of vital signs, observation afterward and written discharge instructions.
  • Follow-up: structured follow-up at regular intervals and coordination with your neurologist and therapists.

A COFEPRIS license authorizes the facility and laboratory to operate. It is not the same as regulatory approval of stem cell therapy as a cure or standard treatment for TBI.

Standard care remains essential

Cell therapy, when used, is an addition to evidence-based TBI care, not a substitute. According to the National Institute of Neurological Disorders and Stroke (NINDS, NIH), treatment for TBI includes medical management of complications, medication when indicated and rehabilitation tailored to physical, cognitive, communication and emotional needs. Continuing these therapies before and after any cell treatment gives the best opportunity for progress and makes outcomes easier to interpret.

Warning signs when researching clinics

Be cautious if a clinic:

  • Promises to cure TBI or restore pre-injury function.
  • Cites success rates without published data.
  • Says the treatment is risk-free.
  • Cannot explain the cell source, dose, route and laboratory testing.
  • Suggests stopping rehabilitation or prescribed medications.
  • Does not request your imaging and medical records before recommending treatment.

The International Society for Stem Cell Research (ISSCR) patient guide offers additional questions to ask before considering any stem cell treatment.

Who may be a candidate

  • Adults or children with stable TBI, usually in the subacute or chronic phase, without rapid neurological decline.
  • Seizures controlled with medication, if present.
  • No active infection or cancer within the past five years.
  • Active participation, or willingness to participate, in rehabilitation.
  • Realistic expectations about partial, variable results.

The final decision depends on a review of your records and a consultation with the doctor.

Questions to ask during your evaluation

  • What improvements are realistic for my type and severity of injury?
  • How will results be measured, and when?
  • Which cell source, dose and route are proposed, and why?
  • What are the possible side effects in my situation?
  • How will treatment be coordinated with my neurologist and rehabilitation team?

Bottom line

Stem cell therapy cannot cure a traumatic brain injury. Evidence from a randomized trial of a specific implanted product shows that cell therapy may improve certain functions in some patients, and safety data for IV umbilical cord MSCs are reassuring; results with IV Wharton's jelly MSCs vary between individuals. The most realistic role for this treatment is as a complement to rehabilitation and standard care. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your injury, goals and medical history.

References

  1. National Institute of Neurological Disorders and Stroke (NINDS, NIH): Traumatic brain injury (opens in a new tab)
  2. Kawabori M et al. Mesenchymal stromal cell implants for chronic motor deficits after traumatic brain injury (STEMTRA trial). Neurology, 2024 (opens in a new tab)
  3. Kawabori M et al. Cell therapy for chronic TBI: interim analysis of the randomized controlled STEMTRA trial. Neurology, 2021 (opens in a new tab)
  4. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
  5. International Society for Stem Cell Research (ISSCR): The ISSCR Guide to Stem Cell Treatments (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation